StoryRegulatory
FDA CVM accepts reasonable expectation of effectiveness for Loyal's LOY-001, a first for a lifespan claim
Loyal completed the technical effectiveness section of its conditional approval application for LOY-001, which the FDA accepted as demonstrating reasonable expectation of effectiveness for large-dog lifespan extension. This marks the FDA's first-ever formal acceptance that a drug can be developed and approved to extend lifespan as its primary claim.
- FDA's first-ever formal acceptance that a drug can be developed and approved to extend lifespan; completed 2,300+ page technical submission.
- Evidence included interventional studies in FDA-accepted canine aging model and observational data from 451 dogs with owner-reported quality of life scores.
- FDA concluded 'LOY-001 is likely to be effective for large dog lifespan extension in the real world'; conditional approval allows market entry pending confirmatory pivotal study over five-year period.